Back in June, the maker of Botox was seeking FDA approval of its eyelash-boosting drug. Now, Allergan got its wish: the FDA has approved Latisse, an eyelash-thickening agent meant for people who have hypotrichosis of the eyelashes — in other words, too few lashes.
Latisse's active ingredient is bimatroprost, which happens to be the same ingredient used in glaucoma treatments. Side effects may include itchy eyes, eye redness, a change in skin color, and a potentially permanent darkening of the iris. For people who have serious eyelash problems, it's probably worth a shot — but considering the possible side effects, I'll stick with my mascara for now.